{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:47:44Z","timestamp":1759366064983,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,10,30]],"date-time":"2015-10-30T00:00:00Z","timestamp":1446163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015699","name":"Fresenius Medical Care North America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015699","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000183","name":"Army Research Office","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000183","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.nefro.2015.10.006","type":"journal-article","created":{"date-parts":[[2015,12,4]],"date-time":"2015-12-04T02:41:21Z","timestamp":1449196881000},"page":"164-175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Anti-parathyroid treatment effectiveness and persistence in incident haemodialysis patients with secondary hyperparathyroidism"],"prefix":"10.1016","volume":"36","author":[{"given":"Angel Luis Mart\u00edn","family":"de Francisco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iain Andrew","family":"Gillespie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioanna","family":"Gioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Floege","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Kronenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Marcelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Collins.","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Froissart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tilman Bernhard.","family":"Drueke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefro.2015.10.006_bib0130","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","article-title":"Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"69","author":"Moe","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefro.2015.10.006_bib0135","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)","author":"Kidney Disease: Improving Global Outcomes CKD-MBD Work Group","year":"2009","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.nefro.2015.10.006_bib0140","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study","volume":"31","author":"Block","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefro.2015.10.006_bib0145","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","article-title":"Association of elevated serum PO(4), Ca\u00ffPO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients","volume":"12","author":"Ganesh","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2015.10.006_bib0150","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1681\/ASN.2004040275","article-title":"Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study","volume":"16","author":"Slinin","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2015.10.006_bib0155","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","article-title":"Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"52","author":"Tentori","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefro.2015.10.006_bib0160","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1093\/ndt\/gfn613","article-title":"Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease","volume":"24","author":"Covic","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2015.10.006_bib0165","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2215\/CJN.01060308","article-title":"Consistent control of mineral and bone disorder in incident hemodialysis patients","volume":"3","author":"Danese","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2015.10.006_bib0170","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/ndt\/gfu015","article-title":"Drug adherence in chronic kidney diseases and dialysis","volume":"30","author":"Burnier","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2015.10.006_bib0175","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/2047-783X-14-5-185","article-title":"Adherence to prescribed oral medication in adult patients undergoing chronic hemodialysis: a critical review of the literature","volume":"14","author":"Schmid","year":"2009","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.nefro.2015.10.006_bib0180","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1053\/j.ajkd.2010.03.002","article-title":"Barriers to adult hemodialysis patients\u2fff self-management of oral medications","volume":"56","author":"Browne","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefro.2015.10.006_bib0185","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2369-14-153","article-title":"Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence","volume":"14","author":"Covic","year":"2013","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.nefro.2015.10.006_bib0190","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1542-4758.2012.00688.x","article-title":"Depression and nonadherence predict mortality in hemodialysis treated end-stage renal disease, patients","volume":"16","author":"Rosenthal Asher","year":"2012","journal-title":"Hemodial Int"},{"key":"10.1016\/j.nefro.2015.10.006_bib0195","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing, dialysis","volume":"367","author":"Evolve Trial Investigators","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefro.2015.10.006_bib0200","doi-asserted-by":"crossref","first-page":"c143","DOI":"10.1159\/000319936","article-title":"An epidemiological study of hemodialysis patients based on the European Fresenius Medical Care hemodialysis network: results of the ARO study","volume":"118","author":"de Francisco","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.nefro.2015.10.006_bib0205","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/ki.2014.419","article-title":"Development and validation of a predictive mortality risk score from a European hemodialysis cohort","volume":"87","author":"Floege","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefro.2015.10.006_bib0210","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1055\/s-0038-1633841","article-title":"EuCliD \u2fff a medical registry","volume":"43","author":"Steil","year":"2004","journal-title":"Methods Inf Med"},{"key":"10.1016\/j.nefro.2015.10.006_bib0215","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1038\/sj.ki.5001868","article-title":"Mortality risk among hemodialysis patients receiving different vitamin D analogs","volume":"70","author":"Tentori","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefro.2015.10.006_bib0220","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1093\/ndt\/gfs018","article-title":"Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study","volume":"27","author":"Ketteler","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2015.10.006_bib0225","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.2215\/CJN.10661013","article-title":"A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3\u2fff4 CKD","volume":"9","author":"Coyne","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2015.10.006_bib0230","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefro.2015.10.006_bib0235","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1681\/ASN.2004060512","article-title":"Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study","volume":"16","author":"Lindberg","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2015.10.006_bib0240","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1046\/j.1523-1755.2003.00720.x","article-title":"The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism","volume":"63","author":"Lindberg","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefro.2015.10.006_bib0245","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/01.ASN.0000050224.03126.AD","article-title":"The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease","volume":"14","author":"Quarles","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2015.10.006_bib0250","first-page":"19","article-title":"Current prescribing of statins and persistence to statins following ACS in the UK: a MINAP\/GPRD study","author":"Boggon","year":"2012","journal-title":"Br J Cardiol"}],"container-title":["Nefrolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0211699515001915?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0211699515001915?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:53:03Z","timestamp":1759323183000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0211699515001915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S0211699515001915"],"URL":"https:\/\/doi.org\/10.1016\/j.nefro.2015.10.006","relation":{},"ISSN":["0211-6995"],"issn-type":[{"type":"print","value":"0211-6995"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-parathyroid treatment effectiveness and persistence in incident haemodialysis patients with secondary hyperparathyroidism","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefro.2015.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.","name":"copyright","label":"Copyright"}]}}